TARS stock forecast
Our latest prediction for Tarsus Pharmaceuticals Inc's stock price was made on the Jan. 20, 2023 when the stock price was at 14.93$.
In the short term (2weeks), TARS's stock price should underperform the market by -3.73%. During that period the price should oscillate between -7.56% and +3.73%.
In the medium term (3months), TARS's stock price should underperform the market by -14.91%. During that period the price should oscillate between -28.10% and +7.52%.
Get email alertsCreate a solid portfolio with TARS
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address a number of diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease.
At the moment the company generates 16M USD in revenues.
On its last earning announcement, the company reported a loss of -2.79$ per share.
The book value per share is 8.02$
Three months stock forecastJan. 20, 2023
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16M | 234.20% | -62M | -384.41% | -53M | -2.79 | - | - | 26M | 8.02 | - | - | - |